By Jonathan Hiles and Ben JonesThe Duke University Medical Center has announced that it will treat patients with neuropsychiatric illnesses like schizophrenia and bipolar disorder using a new type of treatment called DBSX.
The announcement comes as Duke continues to push ahead with its aggressive new approach to the treatment of schizophrenia and depression.
“In a world where the diagnosis of mental illness can be devastating, our research and innovation is creating a better way for people with complex psychiatric illnesses to live healthier lives,” said Dr. Paul M. M. Vinson, vice president for neuroscience research at Duke.
The new DBSx treatment will be used in the Duke Neuropsychiatric Institute, which is part of the Medical School.
It is expected to be available in 2020.
The DBS system uses an MRI to look at the brain in a patient, then uses brain imaging technology to measure the severity of symptoms, symptoms, or depression.
The treatment works by removing the affected areas of the brain and focusing on what is happening in the brain.
“It’s a completely new way to look and understand the brain,” said David J. Scharfenberg, director of Duke Neuropsychoanalysis and director of the Duke Brain and Mind Institute.
The Duke Neuroscientist, or DBS, uses two techniques to look into the brain: neuroimaging and functional magnetic resonance imaging.
This technology uses magnetic pulses to look for abnormalities in the electrical activity of certain parts of the body.
The technique has been used in studies in other brain disorders like autism.
The goal is to create a new and better way of looking at brain activity.
“The brain is the seat of our consciousness, our thoughts and emotions,” said Scharfenburg.
The approach is similar to what other brain-based therapies have been trying to do.
There is no cure for schizophrenia and other psychiatric illnesses, but it has helped patients with a wide range of neurological conditions.
In an interview with the BBC, Dr. Visser said he believes that the DBS approach could be used to help people with depression, schizophrenia, and bipolar.
He also said that he believes it could be useful in people with autism, autism spectrum disorder, and other neurological conditions as well.
This is the first time Duke has used the DTSX technology to treat schizophrenia and major depressive disorder.
It has used it to treat major depression, bipolar disorder, obsessive-compulsive disorder, anxiety, and PTSD.
“The brain has been shown to be highly sensitive to different stressors, and our treatment will help us make better decisions,” said Vissers.
“We believe that the treatment could have an impact on treatment outcomes and prevent relapse.”
In addition to the DFSX treatment, Duke plans to be one of the first institutions in the US to offer DBS to people with a psychotic diagnosis.
It plans to begin testing its DBS treatment in a pilot program later this year.
Scharfenberg said the goal is for DBS treatments to become more widely available.
“What we have found is that the brain is a very rich source of information and can have profound impacts on the quality of life,” he said.
“There are some very basic things we can do to reduce the impact of the disease and to prevent the relapse and the symptoms from becoming chronic.”
The Duke neuroscientist said that if there are problems with the DbsX treatment or there are concerns about the safety of the technology, he is ready to make changes.
“We have a very long way to go before we can be ready to begin treating people,” he added.
“But this is an exciting time in the history of medicine, and we believe this will be a major step forward in the treatment and diagnosis of these diseases.”
For more on schizophrenia and mental health, check out the BBC’s schizophrenia special.